1. Introduction to a Clinical Course On New Developments In Atopic Dermatitis

2. Atopic Dermatitis

3. Program Overview

4. Atopic dermatitis: burden and impact

5. Atopic Dermatitis: Clinical Presentation

6. Psychological Burden of Skin Diseases: Atopic Dermatitis

7. Atopic Dermatitis: Current Management Options

8. Current Management: Moderate to Severe Atopic Dermatitis

9. Case of a Woman With Lifelong History of Atopic Dermatitis

10. Concluding Remarks

11. Characterizing atopic dermatitis: going beneath the skin

12. Introduction

13. Nonlesional Skin in Atopic Dermatitis Shows Abnormal Cytokine Profile

14. Paradigm Shift in the Pathogenesis of Atopic Dermatitis

15. Same Pathways in Adults and Children?

16. Pediatric vs Adult Skin in Atopic Dermatitis

17. Test of Immune Hypothesis With Dupilumab

18. Patients on Higher Doses Achieved EASI-50

19. Reduction in Epidermal Hyperplasia After 4 Weeks of Dupilumab Treatment

20. Suppression of Th2 and Other Axes

21. Other Targets in Clinical Trials for Atopic Dermatitis

22. Concluding Remarks

23. Setting standards in atopic dermatitis management

24. Treatment Guidelines and Recommendations for Atopic Dermatitis

25. Measuring Disease Activity: ETFAD

26. Treatment Options by Grade of Atopic Dermatitis

27. Systemic Immunosuppressants for Severe Atopic Dermatitis

28. Treatment Options for Moderate Atopic Dermatitis

29. Concluding Remarks

30. Biological therapy for atopic dermatitis: new developments

31. Introduction

32. Role of Th2 in Atopic Dermatitis

33. SOLO 1 and 2 Phase 3 Results: Dupilumab

34. SOLO 1 and 2 Phase 3 Results: Depression Scores

35. Interaction With Many Pathways: Example of Cyclosporine

36. SOLO 1 and 2: Safety and Tolerability

37. Dupilumab in Asthma and Nasal Polyps

38. Other Targets in Clinical Trials for Atopic Dermatitis

39. Atopic Dermatitis and Comorbidities

40. Patient Case of Severe Atopic Dermatitis

41. Looking into the future: emerging therapeutic pathways in atopic dermatitis

42. Novel Developments in the Understanding of Atopic Dermatitis

43. Future Potential of New Biologic Therapies

44. Importance of Restoring Barrier Function

45. Concluding Remarks

46. Abbreviations

47. Abbreviations